Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

US2016200733A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016200733-A1
Application numberUS-201414913258-A
CountryUS
Kind codeA1
Filing dateAug 22, 2014
Priority dateAug 23, 2013
Publication dateJul 14, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

Opening claim text (preview).

What is claimed is: 1 . A compound having a structure represented by a formula: wherein each of R 1a and R 1c is independently selected from —F, —Cl, —Br, —OH, C1-C6 alkoxy, C1-C6 monoalkylamino, and C1-C6 dialkylamino; wherein R 1b is selected from hydrogen, halogen, —OH, C1-C6 alkyl, C1-C6 monohaloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkoxy, C1-C6 monoalkylamino, and C1-C6 dialkylamino; or wherein R 1b and R 1c are optionally covalently bonded and, together with the intermediate atoms, comprise a 3- to 7-membered cycle and substituted with 0, 1 or 2 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C6 alkyl, C1-C6 monohaloalkyl, C1-C6 polyhaloalkyl, C1-C6 alkoxy, C1-C6 monoalkylamino, and C1-C6 dialkylamino; wherein R 3 is selected from hydrogen, halogen, —OH, —CN, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 hydroxyalkyl, C1-C8 alkoxy, —CR 10a R 10b OR 11 , —CR 10a R 10b NR 12a R 12b , —S(O) m R 15 , —(C1-C6 alkyl)-Ar 1 , —(C1-C8 alkyl)-Cy 1 , Ar 1 , and Cy 1 ; wherein m is an integer selected from 0, 1, and 2; wherein each of R 10a and R 10b , when present, is independently selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 polyhaloalkyl; wherein R 11 , when present, is selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 polyhaloalkyl; wherein each of R 12a and R 12b , when present, is independently selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 polyhaloalkyl; wherein R 15 , when present, is selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 polyhaloalkyl; wherein each Ar 1 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 1 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, C1-C8 dialkylamino, and —S(O) q R 16 ; wherein each q is an integer independently selected from 0, 1, and 2; wherein each R 16 , when present, is selected from hydrogen, C1-C8 alkyl, C1-C8 haloalkyl, and C1-C8 polyhaloalkyl; wherein each Cy 1 , when present, is independently selected from C3-C9 cycloalkyl and C2-C7 heterocycloalkyl, and wherein each Cy 1 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C8 alkyl, C1-C8 haloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, C1-C8 dialkylamino, and —S(O) q R 16 ; and wherein when Cy 1 is a C2-C7 heterocycloalkyl, the Cy 1 group is bonded to the thieno ring via a carbon-carbon bond; wherein each of R 4a and R 4b is independently selected from hydrogen, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C3-C8 hydroxyalkyl, —(C1-C6 alkyl)-O—(C1-C6 alkyl), —(C1-C6 alkyl)-O—(C1-C6 alkyl)-O—(C1-C6 alkyl), —(C1-C6 alkyl)-NR 40 R 41 , —(C1-C6 alkyl)-NR 40 (C═O)R 41 , —(C1-C6 alkyl)-NR 40 (C═O)OR 41 , —(C1-C6 monohaloalkyl)-NR 40 (C═O)OR 41 , —(C1-C6 polyhaloalkyl)-NR 40 (C═O)OR 41 , —(C1-C8 alkyl)-Cy 2 , Cy 2 , —(C1-C8 alkyl)-Ar 2 , —(C2-C8 alkynyl)-Ar 2 , and Ar 2 ; wherein R 4a and R 4b are not simultaneously hydrogen; wherein each R 40 , when present, is independently selected from hydrogen and C1-C8 alkyl; wherein each R 41 , when present, is independently selected from hydrogen, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, —(C1-C8 alkyl)-Cy 2 , Cy 2 , —(C1-C8 alkyl)-Ar 2 , and Ar 2 ; wherein each Ar 2 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 2 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, —N 3 , —SF 5 , C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, C1-C8 dialkylamino, —(C1-C6 alkyl)-O—(C1-C6 alkyl), —(C1-C6 alkyl)-O—(C1-C6 alkyl)-O—(C1-C6 alkyl), —(C1-C6 alkyl)-NR 51 R 52 , —(C1-C6 alkyl)-NR 50 (C═O)R 55 , —(C1-C6 alkyl)-NR 50 (C═O)OR 55 , —(C1-C6 alkyl)-NR 50 S(O) t R 55 , —NR 50 (C1-C6 alkyl)-(C═O)R 55 , —NR 50 (C1-C6 alkyl)-(C═O)OR 55 , —NR 50 (C1-C6 alkyl)-S(O) t R 55 , —NR 50 (C1-C6 alkyl)-S(O) t NR 53 R 54 , —NR 50 (C═O)R 55 , —NR 50 (C═O)OR 55 , —NR 50 S(O) t R 55 , —(C1-C6 alkyl)-(C═O)R 55 , —(C1-C6 alkyl)-(C═O)OR 55 , —(C1-C6 alkyl)-S(O) t R 55 , —(C1-C6 alkyl)-S(O) t NR 53 R 54 , —(C═O)R 55 , —(C═O)OR 55 , —S(O) t R 55 , —S(O) t NR 53 R 54 , —(C1-C8 alkyl)-Ar 20 , Ar 20 , —(C1-C8 alkyl)-Cy 20 , Cy 20 , and R 57 ; wherein each t is an integer independently selected from 0, 1 and 2; wherein each Ar 20 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 20 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, —S(O) y R 56 , C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, and C1-C8 dialkylamino; wherein each y is an integer independently selected from 0, 1, and 2; wherein each Cy 20 , when present, is independently selected from C3-C9 cycloalkyl and C2-C7 heterocycloalkyl, and wherein each Cy 20 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, —S(O) y R 56 , C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, and C1-C8 dialkylamino; wherein each R 50 , when present, is independently selected from hydrogen and C1-C8 alkyl; wherein each R 51 , when present, is independently selected from hydrogen and C1-C8 alkyl; wherein each R 52 , when present, is independently selected from hydrogen and C1-C8 alkyl; wherein each R 53 , when present, is independently selected from hydrogen and C1-C8 alkyl; wherein each R 54 , when present, is independently selected from hydrogen, C1-C8 alkyl, C3-C9 cycloalkyl, C2-C7 heterocycloalkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, —(C1-C6)-Ar 21 , and Ar 21 ; wherein each Ar 21 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 21 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, and C1-C8 dialkylamino; wherein each R 55 , when present, is independently selected from hydrogen, C1-C8 alkyl, C1-C8 hydroxyalkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C3-C9 cycloalkyl, C2-C7 heterocycloalkyl, —(C1-C6)-Ar 22 , and Ar 22 ; wherein each Ar 22 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 22 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, and C1-C8 dialkylamino; wherein each R 56 , when present, is independently selected from hydrogen, C1-C8 alkyl, C1-C8 hydroxyalkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C3-C9 cycloalkyl, C2-C7 heterocycloalkyl, —(C1-C6)-Ar 23 , and Ar 23 ; wherein each Ar 23 , when present, is independently selected from phenyl, naphthyl, and heteroaryl, and wherein each Ar 23 is independently substituted with 0, 1, 2, or 3 groups independently selected from halogen, —NH 2 , —OH, —CN, C1-C8 alkyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxy, C1-C8 alkylamino, and C1-C8 dialkylamino; wherein each R 57 , when present, is independently selected from C1-C4 alkyl, C1-C4 alkoxy, C1-C4 monoalkylamino, or C1-C4 dialkylamino substituted with 1 or 2 groups selected from —F, —CH 3 , —CF 3 , —OH, —NH 2 , and —CN; wherein each Cy 2 , when present, is independently selected from C3-C9 cycloalkyl and C2-C7 heterocycloalkyl, and wherein each Cy 2 is independently substituted with 0, 1, 2, or

Assignees

Inventors

Classifications

  • C07D495/04Primary

    Ortho-condensed systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016200733A1 cover?
In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychi…
Who is the assignee on this patent?
Univ Vanderbilt
What technology area does this patent fall under?
Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jul 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).